ClinicalTrials.gg
RecruitingNCT06388161Updated Aug 27, 2025

Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology

An observational study in Epilepsy and Encephalitis Autoimmune, sponsored by Shen Chun-Hong. Recruiting at 1 site in China. Open to participants aged 14 Years to 100 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Shen Chun-Hong · Observational

How we know

From the registry’s dates

  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
14 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 101 studies in Epilepsy with a site in China — 35 open to participants now, 41 under way, 5 of them phase 3. Epilepsy · China.

Planned enrollment
17th of 37
300 · median 234
Started
2023
with 7 others
Observational
37 of 101
16 open now
Primary completion
2026-12
later than 16 of 40 live
Registered
72nd of 101
by date

Among the 101 studies in Epilepsy with a site in China, this one is the 17th largest by planned enrollment of the 37 observational ones that give a count, is one of 8 that started in 2023, is one of 37 observational ones, reaches primary completion later than 16 of the 40 other live ones, and was the 72nd registered.

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 418 are open to participants now.

Browse Epilepsy studies →

Open to participants now

35 of the 101 studies in Epilepsy with a site in China are open now. Recruiting first, the newest first:

29 more — sign in →

All 35 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 113 (40%) set no upper age limit and 148 (52%) stop at 75 or younger; 138 take children under 18; 54 take healthy volunteers.

This study: 14 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 101 studies in Epilepsy with a site in China, or all of them as a file.
02

Study summary

Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage.

It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.

Read the detailed description
  1. Focal epileptic seizure or epilepsy is defined according to seizure semiology, electroencephalography findings and/or other relevant information. If applicable, 24 hour video-electroencephalography is performed.
  2. Clinical information is documented by specially-assigned persons, including patient demographics, age at onset, disease duration, seizure semiology, seizure frequency, clinical manifestations, underlying malignancy, hyponatremia, brain MRI, medications and other diseases.
  3. The Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment (MoCA), Hamilton Depression Scale (HAMA), Hamilton Anxiety Scale (HAMA) and the modified Rankin Scale (mRS) at baseline were assessed and recorded.
  4. Previous scoring scales, such as antibody prevalence in epilepsy and encephalopathy (APE2) score, antibodies contributing to focal epilepsy signs symptoms (ACES) score and the "Obvious" Indications for Neural Antibody Testing in Epilepsy or Seizures (ONES) checklist are evaluated at baseline.
  5. Commercial cell-based assay (CBA; EUROIMMUN, Lübeck, Germany) was used to detect serum anti-N-methyl-D-aspartate receptor (anti-NMDAR), anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (anti-AMPAR), anti-γ-aminobutyric acid B receptor (anti-GABABR), anti-leucine-rich glioma-inactivated 1 (anti-LGI1), anti-contactin-associated protein-like 2 (anti-CASPR2), and anti-glutamic acid decarboxylase 65 (anti-GAD65), anti-metabotropic glutamate receptor 5 (mGluR5), anti-dipeptidyl peptidase-like protein 6 (DPPX), anti-myelin oligodendrocyte glycoprotein (MOG) and anti-immunoglobulin-like cell adhesion molecule 5 (IgLON5) antibodies. If serum neural autoantibodies are detected, cerebrospinal fluid should be tested.
03

Conditions studied

  • Epilepsy
  • Encephalitis Autoimmune
04

Who can participate

Ages eligible
14 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who have new-onset focal seizure with unknown etiology; and focal seizure is considered according to the seizure seiology, electroencephalography findings and/or other relevant information.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients have a diagnosis of new-onset focal epileptic seizure or epilepsy and present with their first seizure within the previous 12 months
  • Patients are prospectively recruited from the routine practice of epileptologists in epilepsy centers and epilepsy clinics
  • There is no obvious suspicion of encephalitis
  • Written and sera are obtained
  • Cerebrospinal fluid test must be conducted, when patients have detectable serum autoantibodies

Exclusion criteria

Exclusion Criteria:

  • Patients have other etiology of seizures, such as structure, infection, genetics and metabolism.
  • Written are not obtained
  • Loss of follow-up
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes
Biospecimen retention
Samples without dna
06

What researchers measure

Primary outcomes

  1. Detectable serum neural autoantibodies

    such as NMDAR、AMPAR1、AMPAR2、LGI1、lg LON5、DPPX、GAD65、mGluR5、MOG

    Time frame: at baseline

  2. Neuronal surface antibodies-mediated autoimmune- encephalitis

    diagnosed according to the 2016 diagnostic criteria

    Time frame: at baseline

Secondary outcomes

  1. The proportion of seizure freedom

    We defined seizure freedom according to the International League Against Epilepsy (ILAE) definition

    Time frame: through study completion, an average of 1 year

  2. The proportion of drug-resistent epilepsy

    We defined drug-resistent epilepsy according to the International League Against Epilepsy (ILAE) definition

    Time frame: through study completion, an average of 1 year

  3. Clinical severity and recovery

    modified Rankin scale, ranging from 0-6, higher scores mean a worse outcome

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2026, 40 months after the start.

Of 193 non-industry observational studies under Epilepsy, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 179. This study's planned 40 months is below that.

Counting every sponsor, half of 231 studies reached it within 59 months; a quarter within 24 and three quarters within 109.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2024
First posted
Apr 29, 2024
StartActual
Aug 1, 2023
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2030
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06388161
Lead sponsor
Shen Chun-Hong
Responsible party
Shen Chun-Hong (Associate Senior Doctor, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Sponsor-investigator
First posted
Apr 29, 2024
Start date
Aug 1, 2023
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
Aug 27, 2025

Study contacts

Chun-Hong Shen
Contact
shen_neurology@zju.edu.cn
+86 0571 87783872
Chunhong Shen
principal investigator · Second Affiliated Hospital, School of Medicine, Zhejiang University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion